Company Overview
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +875.46% |
| 6 Months: | +119.31% |
| 3 Months: | +47.63% |
| 1 Month: | +13.57% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.57 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CLYM Climb Bio Inc R3KPHARMA | 15.90 | -19.39 | $913.24M | 0.00% | -42.23% | -27.10% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -1.61M | -2.26M | -6.88M | -8.71M | -9.38M | -13.13M | -13.70M | -8.75M | -23.44M | -6.71M | -5.00M | -3.00M | -56.37M | -11.73M | -23.02M | -10.68M | -14.89M | -15.21M | -15.36M |
| Net Income | -1.63M | -2.26M | -18.60M | -8.72M | -9.62M | -13.20M | -14.60M | -9.68M | -22.29M | -5.22M | -3.97M | -1.70M | -54.89M | -8.89M | -20.78M | -8.67M | -12.89M | -13.72M | -13.50M |
| Diluted EPS | - | - | - | -3.11 | -0.70 | -0.50 | -0.37 | -0.37 | -0.84 | -0.19 | -0.15 | -0.06 | -1.81 | -0.13 | -0.31 | -0.13 | -0.19 | -0.20 | -0.18 |
| R&D Expense | 1.32M | 1.93M | 4.27M | 5.48M | 5.99M | 8.26M | 8.77M | 4.26M | 5.72M | 3.69M | 2.88M | 1.09M | 1.05M | 6.24M | 17.33M | 6.58M | 9.07M | 9.37M | 9.71M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -20.93M | -35.67M | -45.13M | -40.27M | -82.02M | -67.88M |
| Net Income | -20.67M | -47.48M | -45.24M | -35.12M | -73.90M | -59.85M |
| Diluted EPS | - | -4.24 | -1.72 | -1.30 | -1.53 | -0.88 |
| R&D Expense | 8.77M | 23.32M | 26.21M | 15.41M | 14.34M | 46.71M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 24.63M | 173.24M | 134.99M | 110.47M | 217.19M | 167.74M |
| Total Equity | -5.56M | -24.98M | 167.20M | 128.72M | 107.60M | 211.88M | 160.47M |
| Cash & Equivalents | - | 20.49M | 46.92M | 43.59M | 93.11M | 87.23M | 35.69M |
| Total Liabilities | - | 3.06M | 6.04M | 6.28M | 2.87M | 5.31M | 7.27M |
| Current Liabilities | - | 3.06M | 6.03M | 6.10M | 2.83M | 4.93M | 6.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.10M | -36.07M | -37.37M | -20.60M | -15.56M | -54.36M |
| Investing Cash Flow | 8.08M | -114.97M | 34.44M | 68.98M | -121.09M | 2.83M |
| Financing Cash Flow | 4.92M | 177.23M | 0 | 841.00K | 130.73M | -21.00K |
| Capital Expenditure | - | - | - | - | -0 | -186.00K |
| Free Cash Flow | - | - | - | - | -15.56M | -54.54M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 82.7% | -28.4% | -35.2% | -32.6% | -34.9% | -37.3% |
| ROCE % | -97.0% | -21.3% | -35.0% | -37.4% | -38.6% | -42.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 19.68% | 11.30M | $158.78M |
| 2 | FMR, LLC | 11.82% | 6.79M | $95.40M |
| 3 | UBS Group AG | 5.93% | 3.40M | $47.84M |
| 4 | Braidwell LP | 4.87% | 2.80M | $39.30M |
| 5 | Adage Capital Partners GP L.L.C. | 4.36% | 2.51M | $35.21M |
| 6 | Blackrock Inc. | 4.10% | 2.35M | $33.09M |
| 7 | Price (T.Rowe) Associates Inc | 3.70% | 2.13M | $29.89M |
| 8 | Cormorant Asset Management, LP | 3.67% | 2.11M | $29.59M |
| 9 | Frontier Capital Management Company LLC | 3.38% | 1.94M | $27.24M |
| 10 | Vanguard Capital Management LLC | 2.96% | 1.70M | $23.87M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLYM
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1vUmM0clM3Sk1UTW9Mem9mcU1MWmFyejZEbFE2allVNlZkTjJlb2k3Z3Bncmt5Y0xyRnNlMnVwcjJRa1dFTUZuQ2Q4SzZLX2gy?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
CLYM Stock Price, Quote & Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE54ZTI3dTZiek9VRHM5aHhBOHl3V08teUt2Vmx3YXhzam1sclgybUo3RnI5RmJ1Q1REME5wS05OOVlnNW56c1NmRVp0WGJuR2FxcXM3ZFVLUWJSQUZ1dnFr?oc=5" target="_blank">CLYM Stock Price, Quote & Chart</a>&nbs…
Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPTFFzTGJSQ1BUby1wMDlSYWlCWlR1V1p6alJ4aXI5V1RVUS1FZ3hkMGxHRnFBVWhTamJONEg2Y1E2TDdRRFNiRkVPZDZ1NjkxQzFPSTlpNTBGRzU2Sk1SYjkza2p0Y1NEZkhTUkd4d1B4bVJpOG1BdHNYRWlLbmtqRW5wT2Y2bEJaeDkycW…
Technical Reactions to CLYM Trends in Macro Strategies - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPRy1IX0RmUjM0UmhXYXo2U1BzV1Q5WWl3RDZlNkdBc2diZDFJLXB3bWw1NURCX19SblJhZ2p1UWxEcXZaTU43X0dmRWRvYXp5R0pxVlNmR0pHQ3pVQl96MU56Wm12NjNkMEI4ZHJRUWdSaEVpYUZpMzRkakliZTF6eldSMkN3d2JCcGN6aT…
Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNQXBldlgzQVNVV0hpY3UzeUVaQWJncDBIcXM2Q2JYSFp0Nk51NHd4ZnhXRTRlUDlCYVdaWGhkT2d6QkJ3LVlqaDAxRXZJSG0wRFota1lIeUUxNlVqOXNtTi00dVA3U1NWazdvdXVveGtOdGRBaXhpSGg4WHYxOWtFZmdFbUJ1Y2NvWDFCbV…
$CLYM stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNT1luSjYydlgtUldYZW1MSVNISS1VTTU3bE00U1J2M3BKZU85X0RpQU5pcE4ydjBsczdFUWlDUFlrd25yclhzTGx3MWdSWXlKSV8tQXVaWmZaSzFWVGgzOV9qWGFJQlhkRTdkLTBnZnBxVkNGZFJLTk9nN182Wkp0R2l4OTlER2NYTFByT2…
CLYM — Frequently Asked Questions
What is the current share price of Climb Bio Inc (CLYM)?
As of 2026-09-19 21:16 PDT, Climb Bio Inc (CLYM) trades at $15.90 on NasdaqGM. Its 52-week range is $1.63 to $17.84.
What is the market capitalisation of CLYM?
Climb Bio Inc (CLYM) has a market capitalisation of $913.24M on NasdaqGM.
What is the P/E ratio of CLYM?
CLYM trades at a trailing price-to-earnings (P/E) ratio of -19.39. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.61.
What is the return on equity (ROE) of CLYM?
CLYM has a return on equity (ROE) of -27.10%. Its return on capital employed (ROCE) is -42.23%.
Is CLYM a good stock to buy?
This page provides a data-driven analysis of Climb Bio Inc (CLYM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.